KRAS and adenocarcinoma: The G12/C codon change appears particularly enriched in these KRAS mutant NSCLC adenocarcinomas and promotes epithelial-mesenchymal transition (EMT)-linked disease progression (Patricelli et al., 2016; Janes et al., 2018).